Pregnenolone Succinate
drug drugOn this page
Also known as ArthenoloneEneloneNSC-1616NSC-18158NSC-759188PregnenolonaPregnenolone
Summary
Pregnenolone Succinate (CHEMBL2105373) is a phase-3 clinical-stage small molecule; indicated across 11 conditions including autism and injury.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 11 conditions
- Clinical trials: 34
- Chemistry: 416.5 Da · C25H36O5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2105373 |
| Name | Pregnenolone Succinate |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 10070529 |
| Molecular formula | C25H36O5 |
| Molecular weight | 416.5 |
| InChIKey | OZZAYJQNMKMUSD-DMISRAGPSA-N |
SMILES: CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)CCC(=O)O)C)C
IUPAC name: 4-[[(3S,8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4-oxobutanoic acid
Also known as: Arthenolone, Enelone, NSC-1616, NSC-18158, NSC-759188, Pregnenolona, Pregnenolone, Pregnenolone succinate, PREGNENOLONE SUCCINATE
Patent coverage: 369 distinct patent families (730 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Glutamate NMDA receptor; Grin1/Grin2b.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
9 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| autism | 2 | MONDO:0005260 | EFO:0003758 |
| injury | 2 | MONDO:0021178 | EFO:0000546 |
| substance withdrawal syndrome | 2 | MONDO:0005567 | EFO:0005800 |
| post-traumatic stress disorder | 2 | MONDO:0005146 | EFO:0001358 |
| cannabis dependence | 2 | MONDO:0005689 | EFO:0007191 |
| schizoaffective disorder | 2 | MONDO:0005487 | EFO:0005411 |
| alcohol abuse | 2 | MONDO:0002046 | MONDO:0007079 |
| brain injury | 2 | MONDO:0043510 | MONDO:0043510 |
| autism spectrum disorder | 2 | MONDO:0005258 | EFO:0003756 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 34.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 17 |
| PHASE1 | 6 |
| PHASE4 | 4 |
| Not specified | 4 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00223197 | PHASE4 | COMPLETED | Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse |
| NCT00847600 | PHASE4 | COMPLETED | Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia |
| NCT01409096 | PHASE4 | COMPLETED | Study Using Pregnenolone to Treat Bipolar Depression |
| NCT02582905 | PHASE4 | COMPLETED | Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders |
| NCT00894842 | PHASE2/PHASE3 | COMPLETED | Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia |
| NCT05570812 | PHASE2 | RECRUITING | Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV |
| NCT05781009 | PHASE2 | RECRUITING | Pregnenolone for the Treatment of Alcohol Use Disorder |
| NCT05935761 | PHASE2 | NOT_YET_RECRUITING | Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial |
| NCT06188923 | PHASE2 | RECRUITING | A New Intervention to Improve Function in Veterans With Anxiety and Depression |
| NCT07216690 | PHASE2 | RECRUITING | Pregnenolone as a Treatment for Cannabis Intoxication |
| NCT00615511 | PHASE2 | COMPLETED | Efficacy of Pregnenolone in Patients With Schizophrenia |
| NCT00900900 | PHASE2 | COMPLETED | The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers |
| NCT00993629 | PHASE2 | WITHDRAWN | Adjunctive Pregnenolone in Post-Traumatic Stress Disorder (PTSD) and Depression in Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans |
| NCT01336413 | PHASE2 | COMPLETED | Neuroactive Steroids and Traumatic Brain Injury (TBI) in OEF/OIF Veterans |
| NCT01881737 | PHASE2 | COMPLETED | A Study of Pregnenolone in the Treatment of Individuals With Autism |
| NCT01898013 | PHASE2 | COMPLETED | Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans |
| NCT01956279 | PHASE2 | COMPLETED | Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI) |
| NCT02439814 | PHASE2 | COMPLETED | Pregnenolone and Marijuana Dependence |
| NCT02627508 | PHASE2 | COMPLETED | Pilot Trial of Pregnenolone in Autism |
| NCT02826577 | PHASE2 | TERMINATED | Effects of Pregnenolone on Perceived Social Isolation |
| NCT03505905 | PHASE1/PHASE2 | COMPLETED | A Neurosteroid Intervention for Menopausal and Perimenopausal Depression |
| NCT03799562 | PHASE2 | COMPLETED | Neurosteroids for PTSD in Veterans |
| NCT05671692 | PHASE2 | SUSPENDED | Novel Intervention for Chronic Complex TBI in OEF/OIF/OND Veterans |
| NCT00174889 | PHASE1 | COMPLETED | Pregnenolone in the Management of Schizophrenia Patients |
| NCT00608686 | PHASE1 | UNKNOWN | Neurosteroids and Acute Alcohol Intoxication in Humans |
| NCT02576912 | PHASE1 | COMPLETED | Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone |
| NCT02811939 | PHASE1 | COMPLETED | Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I |
| NCT03645096 | PHASE1 | COMPLETED | Development of Pregnenolone as a Treatment for Depression |
| NCT04464148 | PHASE1 | WITHDRAWN | Feasibility Trial of Pregnenolone for Posttraumatic Stress Disorder and Alcohol Use Disorder |
| NCT03953612 | EARLY_PHASE1 | COMPLETED | The Role of Neuroactive Steroids in Stress, Drug Craving and Drug Use in Cocaine Use Disorders |
| NCT06238700 | Not specified | RECRUITING | Study on Allopregnanolone and Depression in Women Across the Menopause Transition |
| NCT00560937 | Not specified | COMPLETED | Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia |
| NCT00623506 | Not specified | COMPLETED | Adjunctive Pregnenolone in Veterans With Mild TBI |
| NCT01831986 | Not specified | UNKNOWN | Pregnenolone and L-theanine Augmentation in the Treatment for Schizophrenia and Schizoaffective Disorders |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).